Market Research Logo

Point of Care Diagnostics (POCD) Global Market - Forecast to 2023

Point of Care Diagnostics (POCD) Global Market - Forecast to 2023

Point of care tests, also called near-patient testing or bedside testing, refers to the performance of diagnostic tests at or near the site where the patient is located and helps in obtaining accurate results in a very short period of time. It can be performed by non-laboratory personnel and the main benefit of POCT is to make tests more convenient and immediately to the patient that helps doctors/physician to receive the results quicker, enabling clinicians to support the timely diagnosis, monitoring, and treatment of patients. It can be performed by non-laboratory personnel and the results are used for clinical decision making. POCD is usually used in clinics, healthcare departments, hospitals, and patient’s homes. In hospitals, they are primarily performed in emergency departments, surgical suites, critical care units, and certain outpatient areas. POC tests can be performed by a wide variety of people can, including laboratory professionals, emergency first responders, radiologists, doctors, nurses, physician assistants, or other healthcare practitioners. They may even be done by patients, sometimes called "self-tests" or "home tests”. POCT has a range of complexity and procedures that vary from manual methodologies to automated analyzers. With the advancements in technology, POC testing analyzers are becoming smaller, faster, and more user-friendly and to achieve accuracy with increasingly smaller samples (body fluids). The point of care diagnostics global market is expected to grow at single digit CAGR to reach $26,331.1 million by 2023.

The Point of care diagnostics market is segmented based on their products, technology, prescription mode, sample types, end-users, and geography. The global POCD market by products is segmented into glucose monitoring kits, infectious diseases testing kits, coagulation monitoring kits, hematology testing kits, pregnancy and fertility testing kits, cardiometabolic testing kits, tumor/cancer markers, urinalysis kits, cholesterol testing kits, drugs-of-abuse testing kits and others. The glucose monitoring kits are further segmented into self-glucose monitoring and continuous glucose monitoring kits. The Infectious diseases kits are further divided into HIV testing kits, Hepatitis testing kits, Tropical diseases testing kits, tuberculosis testing kits, Healthcare–Associated infection testing kits, respiratory infections testing kits, and others. The coagulation monitoring testing kits are further segmented into Prothrombin Time(PT/INR) Testing Kits and Activated Clotting Time(ACT/APTT) Testing Kits. The Pregnancy and Fertility Testing Kits are further segmented into Pregnancy Testing Kits and Fertility Testing Kits. The Cardiometabolic Monitoring Kits further segmented into Cardiac Markers, Blood Gas/Electrolytes Testing Kits, HBA1C Testing Kits, and LIPID Testing Kits. By technology, the POCD market is divided into a biosensor,microfluidics/lab-on-a-chip technology, PCR technology, Immunochromatographic/lateral flow technology and others. Based on prescription mode, POCD market is segmented into prescription based tests and over the counter tests. By sample types, POCD market is divided into blood, urine, saliva and others. Based on end-users, POCD market is segmented into hospitals, home healthcare, clinics. Further, the POCD global market is separated by geographical regions into North America, Europe, Asia-pacific and Rest of the World.


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 REPORT DESCRIPTION
2.3 MARKETS COVERED
2.4 STAKEHOLDERS
2.5 RESEARCH METHODOLOGY
2.5.1 MARKET SIZE ESTIMATION
2.5.2 MARKET CRACKDOWN AND DATA TRIANGULATION
2.5.4 SECONDARY SOURCES
2.5.5 PRIMARY SOURCES
2.5.6 KEY DATA POINTS FROM SECONDARY SOURCES
2.5.7 KEY DATA POINTS FROM PRIMARY SOURCES
2.5.8 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.4 MARKET DYNAMICS
3.4.1 DRIVERS AND OPPORTUNITIES
3.4.1.1 Rapid rise in the aging population
3.4.1.2 High prevalence of chronic and infectious diseases
3.4.1.3 Lack of skilled laboratory technicians in emerging countries
3.4.1.4 Rising number of clia-waived poc tests
3.4.1.5 Rising awareness about point of care diagnostics in developing countries
3.4.1.6 Technological advancements
3.4.2 RESTRAINTS AND THREATS
3.4.2.1 Inconsistent reimbursement and high cost of devices
3.4.2.2 Stringent regulatory requirements
3.4.2.3 Rising incidence of product recalls
3.4.2.4 Accuracy issues
3.5 REGULATORY AFFAIRS
3.5.1 U.S.
3.5.2 EUROPE
3.5.3 INDIA
3.5.4 CHINA
3.5.5 JAPAN
3.6 PORTER’S FIVE FORCE ANALYSIS
3.6.1 THREAT OF NEW ENTRANTS
3.6.2 THREAT OF SUBSTITUTES
3.6.3 BARGAINING POWER OF SUPPLIERS
3.6.4 BARGAINING POWER OF BUYERS
3.6.5 RIVALRY AMONG EXISTING COMPETITORS
3.7 MARKET SHARE ANALYSIS
3.7.1 MARKET SHARE ANALYSIS OF GLUCOSE MONITORING KITS
3.7.2 MARKET SHARE ANALYSIS OF CONTINUOUS GLUCOSE KITS
3.7.3 MARKET SHARE ANALYSIS OF COAGULATION TESTING KITS
3.7.4 MARKET SHARE ANALYSIS OF CARDIAC MARKERS
3.8 TECHNOLOGICAL ADVANCEMENTS
3.8.1 SMARTPHONE-BASED TECHNOLOGIES
3.8.2 NANOBIOSENSOR
3.8.3 SMART CONTACT LENSES
3.8.4 LIQUID BIOPSY
3.9 FUNDING SCENARIO
3.10 SUPPLY CHAIN ANALYSIS
4 POINT OF CARE DIAGNOSTICS GLOBAL MARKET, BY PRODUCTS
4.1 INTRODUCTION
4.2 GLUCOSE MONITORING KITS
4.2.1 SELF-GLUCOSE MONITORING KITS
4.2.2 CONTINUOUS GLUCOSE MONITORING KITS
4.3 INFECTIOUS DISEASES TESTING KITS
4.3.1 HIV TESTING KITS
4.3.2 HEPATITIS TESTING KITS
4.3.3 TROPICAL DISEASES TESTING KITS
4.3.4 TUBERCULOSIS TESTING KITS
4.3.5 HEALTHCARE-ASSOCIATED INFECTION TEST KITS
4.3.6 RESPIRATORY INFECTIONS TESTING KITS
4.3.7 OTHER INFECTIOUS DISEASE TESTING KITS.
4.3.8 EBOLA VIRUS DISEASE
4.3.9 SYPHILIS
4.4 COAGULATION MONITORING KITS
4.4.1 PROTHROMBIN TIME (PT/INR) TESTING KITS
4.4.2 ACTIVATED CLOTTING TIME (ACT/APTT) TESTING KITS
4.5 HEMATOLOGY TESTING KITS
4.6 PREGNANCY AND FERTILITY TESTING KITS
4.6.1.1 Pregnancy testing kit
4.6.1.2 Fertility testing kit
4.7 CARDIOMETABOLIC MONITORING KITS
4.7.1 CARDIAC MARKERS
4.7.2 BLOOD GAS ANALYZERS/ELECTROLYTES TESTING KITS
4.7.3 HBA1C TESTING KITS
4.7.4 LIPID TESTING KITS
4.8 TUMOR/CANCER MARKERS
4.9 URINALYSIS
4.10 CHOLESTEROL TESTING KITS
4.11 DRUGS-OF-ABUSE TESTING KITS
4.12 OTHERS
4.12.1 OPHTHALMIC TESTING KITS
4.13 GENETIC MARKERS/TESTING KITS
4.13.1 THERAPEUTIC DRUG MONITORING TESTS
4.13.2 BLOOD LACTATE TEST
4.14 FAECAL OCCULT BLOOD TESTING KITS
5 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 BIOSENSOR TECHNOLOGY
5.3 IMMUNOCHROMATOGRAPHIC/LATERAL FLOW TECHNOLOGY
5.4 POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY
5.5 MICROFLUIDIC/LAB-ON-A–CHIP TECHNOLOGY
5.6 OTHER TECHNOLOGIES
6 POINT OF CARE DIAGNOSTICS MARKET, BY PRESCRIPTION MODE
6.1 INTRODUCTION
6.1.1 PRESCRIPTION BASED TESTING KITS
6.1.2 OVER THE COUNTER (OTC) TESTING KITS MARKET
7 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE TYPE
7.1 INTRODUCTION
7.1.1 BLOOD
7.1.2 URINE
7.1.3 SALIVA
7.1.4 OTHER
8 POINT OF CARE DIAGNOSTICS GLOBAL MARKET, BY END USER
8.1 INTRODUCTION
8.2 CLINICS
8.3 HOSPITALS
8.4 HOME HEALTHCARE
8.5 OTHER END-USERS
9 REGIONAL MARKET ANALYSIS
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 U.S.
9.2.2 OTHERS
9.3 EUROPE
9.4 GERMANY
9.4.1 ITALY
9.4.2 FRANCE
9.4.3 OTHERS
9.5 ASIA PACIFIC
9.5.1 JAPAN
9.5.2 CHINA
9.5.3 INDIA
9.5.4 OTHERS
9.6 REST OF THE WORLD
9.6.1 BRAZIL
9.6.2 REST OF LATIN AMERICA
9.6.3 MIDDLE EAST AND OTHERS
10 COMPANY DEVELOPMENTS
10.1 INTRODUCTION
10.2 APPROVALS
10.3 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
10.4 NEW PRODUCT LAUNCH
10.5 ACQUISITIONS
10.6 OTHER DEVELOPMENTS
11 MAJOR COMPANIES
11.1 ABBOTT LABORATORIES, INC
11.1.1 OVERVIEW
11.1.2 FINANCIALS
11.1.3 PRODUCT PORTFOLIO
11.1.4 KEY DEVELOPMENTS
11.1.5 BUSINESS STRATEGY
11.1.6 SWOT ANALYSIS
11.2 ASCENSIA DIABETES CARE HOLDINGS AG.
11.2.1 OVERVIEW
11.2.2 FINANCIALS
11.2.3 PRODUCT PORTFOLIO
11.2.4 KEY DEVELOPMENTS
11.2.5 BUSINESS STRATEGY
11.2.6 SWOT ANALYSIS
11.3 BECTON DICKINSON AND COMPANY
11.3.1 OVERVIEW
11.3.2 FINANCIALS
11.3.3 PRODUCT PORTFOLIO
11.3.4 KEY DEVELOPMENTS
11.3.5 BUSINESS STRATEGY
11.3.6 SWOT ANALYSIS
11.4 BIOMERIEUX
11.4.1 OVERVIEW
11.4.2 FINANCIALS
11.4.3 PRODUCT PORTFOLIO
11.4.4 KEY DEVELOPMENTS
11.4.5 BUSINESS STRATEGY
11.4.6 SWOT ANALYSIS
11.5 DANAHER CORPORATION
11.5.1 OVERVIEW
11.5.2 FINANCIALS
11.5.3 PRODUCT PORTFOLIO
11.5.4 KEY DEVELOPMENTS
11.5.5 BUSINESS STRATEGY
11.5.6 SWOT ANALYSIS
11.6 DEXCOM INC.
11.6.1 OVERVIEW
11.6.2 FINANCIALS
11.6.3 PRODUCT PORTFOLIO
11.6.4 KEY DEVELOPMENTS
11.6.5 BUSINESS STRATEGY
11.6.6 SWOT ANALYSIS
11.7 F.HOFFMANN-LA ROCHE HOLDINGS AG
11.7.1 OVERVIEW
11.7.2 FINANCIALS
11.7.3 PRODUCT PORTFOLIO
11.7.4 KEY DEVELOPMENTS
11.7.5 BUSINESS STRATEGY
11.7.6 SWOT ANALYSIS
11.8 JOHNSON & JOHNSON
11.8.1 OVERVIEW
11.8.2 FINANCIALS
11.8.3 PRODUCT PORTFOLIO
11.8.4 KEY DEVELOPMENTS
11.8.5 BUSINESS STRATEGY
11.8.6 SWOT ANALYSIS
11.9 MEDTRONIC PLC
11.9.1 OVERVIEW
11.9.2 FINANCIALS
11.9.3 PRODUCT PORTFOLIO
11.9.4 KEY DEVELOPMENTS
11.9.5 BUSINESS STRATEGY
11.9.6 SWOT ANALYSIS
11.10 NOVA BIOMEDICAL
11.10.1 OVERVIEW
11.10.2 FINANCIALS
11.10.3 PRODUCT PORTFOLIO
11.10.4 KEY DEVELOPMENTS
11.10.5 BUSINESS STRATEGY
11.10.6 SWOT ANALYSIS
11.11 SIEMENS AG
11.11.1 OVERVIEW
11.11.2 FINANCIALS
11.11.3 PRODUCT PORTFOLIO
11.11.4 KEY DEVELOPMENTS
11.11.5 BUSINESS STRATEGY
11.11.6 SWOT ANALYSIS
11.12 THERMOFISHER SCIENTIFIC INC.
11.12.1 OVERVIEW
11.12.2 FINANCIALS
11.12.3 PRODUCT PORTFOLIO
11.12.4 KEY DEVELOPMENTS
11.12.5 BUSINESS STRATEGY
11.12.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 POCD GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 2 POCD GLOBAL MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
TABLE 3 POCD GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 4 POCD GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 5 POCD GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 6 SELF GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 7 CONTINUOUS GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 8 POCD INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 9 POCD INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 10 HIV KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 11 HEPATITIS KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 12 TROPICAL DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 13 TUBERCULOSIS KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 14 HEALTHCARE-ASSOCIATED DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 15 RESPIRATORY DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 16 OTHER INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 17 POCD COAGULATION KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 18 POCD COAGULATION KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 19 PROTHROMBIN TIME(PT/INR) TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 20 ACTIVATED CLOTTING TIME(ACT/APTT) TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 21 POCD HEMATOLOGY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 22 POCD PREGNANCY AND FERTILITY KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 23 POCD PREGNANCY AND FERTILITY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 24 PREGNANCY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 25 FERTILITY TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 26 POCD CARDIOMETABOLIC KITS GLOBAL MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 27 POCD CARDIOMETABOLIC KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 28 POCD CARDIAC MARKERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 29 POCD BLOOD GAS/ELECTROLYTES TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 30 POCD HBA1C TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 31 POCD LIPID TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 32 POCD TUMOR/CANCER MARKERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 33 POCD URINALYSIS TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 34 POCD CHOLESTEROL TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 35 POCD DRUGS-OF-ABUSE TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 36 POCD OTHER TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 37 POCD GLOBAL MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
TABLE 38 POCD BIOSENSOR TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 39 POCD IMMUNOCHROMATOGRAPHIC TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 40 POCD PCR TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 41 POCD LAB-ON-A-CHIP TECHNOLOGY GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 42 POCD OTHER TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 43 POCD GLOBAL MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
TABLE 44 PRESCRIPTION BASED TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 45 OVER THE COUNTER TESTING KITS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 46 POCD GLOBAL MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
TABLE 47 POCD BLOOD SAMPLE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 48 POCD URINE SAMPLE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 49 POCD SALIVA SAMPLE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 50 POCD OTHER SAMPLES GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 51 POCD GLOBAL MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
TABLE 52 POCD CLINICS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 53 POCD HOSPITALS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 54 POCD HOME HEALTHCARE GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 55 POCD OTHER END-USERS GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
TABLE 56 NORTH AMERICAN POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
TABLE 57 NORTH AMERICAN POCD GLUCOSE MONITORING KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 58 NORTH AMERICAN POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 59 NORTH AMERICAN POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 60 NORTH AMERICAN POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 61 NORTH AMERICAN POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 62 NORTH AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
TABLE 63 NORTH AMERICAN POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
TABLE 64 NORTH AMERICAN POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
TABLE 65 NORTH AMERICAN POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
TABLE 66 NORTH AMERICAN POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
TABLE 67 EUROPEAN POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
TABLE 68 EUROPEAN POCD GLUCOSE MONITORING KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 69 EUROPEAN POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 70 EUROPEAN POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 71 EUROPEAN POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 72 EUROPEAN POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 73 EUROPEAN POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
TABLE 74 EUROPEAN POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
TABLE 75 EUROPEAN POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
TABLE 76 EUROPEAN POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
TABLE 77 EUROPEAN POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
TABLE 78 APAC POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
TABLE 79 APAC POCD GLUCOSE MONITORING KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 80 APAC POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 81 APAC POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 82 APAC POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 83 APAC POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 84 APAC POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
TABLE 85 APAC POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
TABLE 86 APAC POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
TABLE 87 APAC POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
TABLE 88 APAC POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
TABLE 89 ROW POCD MARKET REVENUE, BY PRODUCTS (2015-2023) ($MN)
TABLE 90 ROW POCD GLUCOSE MONITORING KITS MARKET REVENUE BY TYPE (2015-2023) ($MN)
TABLE 91 ROW POCD INFECTIOUS DIASEASE KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 92 ROW POCD COAGULATION KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 93 ROW POCD PREGNANCY AND FERTILITY KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 94 ROW POCD CARDIOMETABOLIC KITS MARKET REVENUE, BY TYPE (2015-2023) ($MN)
TABLE 95 ROW POCD MARKET REVENUE, BY TECHNOLOGY (2015-2023) ($MN)
TABLE 96 ROW POCD MARKET REVENUE, BY PRESCRIPTION MODE (2015-2023) ($MN)
TABLE 97 ROW POCD MARKET REVENUE, BY SAMPLE (2015-2023) ($MN)
TABLE 98 ROW POCD MARKET REVENUE, BY END-USERS (2015-2023) ($MN)
TABLE 99 ROW POCD MARKET REVENUE, BY COUNTRY (2015-2023) ($MN)
TABLE 100 APPROVALS (2015-2017)
TABLE 101 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS (2015-2017)
TABLE 102 NEW PRODUCT LAUNCH(2015-2017)
TABLE 103 ACQUISITIONS (2015-2017)
TABLE 104 OTHER DEVELOPMENTS (2015-2017)
TABLE 105 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 106 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 107 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 108 BECTON DICKINSON AND COMPANY: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 109 BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 110 BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY LIFE SCIENCE SEGMENTS, (2014-2016) ($MN)
TABLE 111 BECTON DICKINSON AND COMPANY: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 112 BIOMEREIUX: TOTAL REVENUE AND R&D EXPENSES, (2014-2016*) ($MN)
TABLE 113 BIOMERIEUX: TOTAL REVENUE,BY SEGMENTS, (2014-2016*) ($MN)
TABLE 114 BIOMEREIUX: TOTAL REVENUE, BY CLINICAL SEGMENTS, (2014-2016*) ($MN)
TABLE 115 BIOMEREIUX: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016*) ($MN)
TABLE 116 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 117 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 118 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016*) ($MN)
TABLE 119 DEXCOM INC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
TABLE 120 DEXCOM INC: TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
TABLE 121 ROCHE HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 122 ROCHE HOLDINGS AG: TOTAL REVENUE BY SEGMENTS, (2014-2016) ($MN)
TABLE 123 ROCHE HOLDINGS AG: DIAGNOSTICS REVENUE BY TYPES, (2014-2016) ($MN)
TABLE 124 ROCHE HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 125 JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 126 JOHNSON & JOHNSON: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 127 JOHNSON & JOHNSON: TOTAL REVENUE, BY MEDICAL DEVICE SEGMENTS, (2014-2016) ($MN)
TABLE 128 JOHNSON & JOHNSON: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 129 MEDTRONIC PLC: TOTAL REVENUE AND R&D EXPENSES (2014-2016) ($MN)
TABLE 130 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 131 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
TABLE 132 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES, (2014-2016) ($MN)
TABLE 133 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, (2014-2016) ($MN)
TABLE 134 SIEMENS AG : TOTAL REVENUE, BY GEOGRAPHY (2014-2016) ($MN)
TABLE 135 THERMOFISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 136 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY SEGMENTS, (2014-2016) ($MN)
TABLE 137 THERMO FISHER SCIENTIFIC, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2014-2016) ($MN)
LIST OF FIGURES
FIGURE 1 POCD GLOBAL MARKET REVENUE, BY REGION (2015-2023) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: POINT OF CARE DIAGNOSTICS GLOBAL MARKET
FIGURE 3 POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 POINT OF CARE DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 POINT OF CARE DIAGNOSTICS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
FIGURE 6 POINT OF CARE DIAGNOSTICS MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 POINT OF CARE DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 POINT OF CARE DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016
FIGURE 10 GLUCOSE MONITORING KITS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
FIGURE 11 CONTINUOUS GLUCOSE MONITORING KITS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
FIGURE 12 COAGULATION TESTING KITS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
FIGURE 13 CARDIAC MARKERS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2016 (%)
FIGURE 14 POINT OF CARE DIAGNOSTICS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 15 POCD GLOBAL MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 16 POCD GLUCOSE MONITORING KITS GLOBAL MARKET REVENUE, BY TYPE (2016 V/S 2023) ($MN)
FIGURE 17 POCD INFECTIOUS DISEASE KITS GLOBAL MARKET REVENUE, BY TYPE (2016 V/S 2023) ($MN)
FIGURE 18 POCD COAGULATION MONITORING KITS GLOBAL MARKET REVENUE, BY TYPE (2015 V/S 2023) ($MN)
FIGURE 19 POCD GLOBAL MARKET REVENUE, BY REGION (2015 V/S 2023) ($MN)
FIGURE 20 POCD CARDIOMETABOLIC KITS GLOBAL MARKET REVENUE, BY TYPE (2016 V/S 2023) ($MN)
FIGURE 21 POCD GLOBAL MARKET REVENUE, BY TECHNOLOGY, (2016 V/S 2023) ($MN)
FIGURE 22 POCD GLOBAL MARKET REVENUE, BY PRESCRIPTION MODE, (2016 V/S 2023) ($MN)
FIGURE 23 POCD GLOBAL MARKET REVENUE, BY SAMPLE (2016 V/S 2023) ($MN)
FIGURE 24 POCD GLOBAL MARKET REVENUE, BY END-USERS (2016 V/S 2023) ($MN)
FIGURE 25 POCD GLOBAL MARKET REVENUE, BY REGION, (2015-2023) ($MN)
FIGURE 26 NORTH AMERICAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 27 NORTH AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 28 U.S. POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 29 U.S. POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 30 OTHERS NORTH AMERICAN POCD MARKET SHARE, BY PRODUCTS, (2016 V/S 2023) ($MN)
FIGURE 31 OTHERS NORTH AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 32 EUROPEAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 33 EUROPEAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 34 GERMANY POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 35 GERMANY POCD MARKET SHARE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 36 ITALY POCD MARKET REVENUE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 37 ITALY POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 38 FRANCE POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 39 FRANCE POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 40 OTHERS EUROPEAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 41 OTHERS EUROPEAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 42 APAC POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 43 APAC POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 44 JAPAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 45 JAPAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 46 CHINA POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 47 CHINA POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 48 INDIAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 49 INDIAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 50 OTHERS APAC POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 51 OTHERS APAC POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 52 ROW POCD MARKET SHARE, BY PRODUCTS, (2016 V/S 2023) (%)
FIGURE 53 ROW POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 54 BRAZIL POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 55 BRAZIL POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 56 REST OF LATIN AMERICAN POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 57 REST OF LATIN AMERICAN POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 58 MIDDLE EAST & OTHERS POCD MARKET SHARE, BY PRODUCTS (2016 V/S 2023) (%)
FIGURE 59 MIDDLE EAST & OTHERS POCD MARKET REVENUE, BY TECHNOLOGY, PRESCRIPTION MODE, SAMPLE TYPE & END-USERS (2016 V/S 2023) ($MN)
FIGURE 60 KEY GROWTH STRATEGIES, (2015-2017)
FIGURE 61 SWOT: ABBOTT LABORATORIES, INC
FIGURE 62 SWOT: ASCENSIA DIABETES CARE
FIGURE 63 SWOT: BECTON DICKINSON AND COMPANY
FIGURE 64 SWOT: BIOMEREIUX
FIGURE 65 SWOT: DANAHER CORPORATION
FIGURE 66 SWOT: DEXCOM INC.
FIGURE 67 SWOT: ROCHE HOLDINGS
FIGURE 68 SWOT: JOHNSON & JOHNSON
FIGURE 69 SWOT: MEDTRONIC PLC
FIGURE 70 SWOT: NOVA BIOMEDICAL
FIGURE 71 SWOT: SIEMENS AG
FIGURE 72 SWOT: THERMOFISHER SCIENTIFIC

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report